{
  "docId": "019de073-8606-762c-9e2e-06d280bc8199",
  "docSlug": "fe3546a131d6b03dbc05b580d2cda1c4",
  "documentTitle": "CTI BioPharma | Investor Presentation Deck | 24 slides",
  "authorId": "cti-biopharma",
  "authorName": "CTI BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 24,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a biological pathway diagram to explain the mechanism of action.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8606-762c-9e2e-06d280bc8199/6",
  "deckHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199",
  "deckJsonHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199.json",
  "deckAnchorHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.25,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "JAK-STAT and TLR/IL1R-IRAK1 pathway inhibition diagram",
      "attrs": null,
      "subkind": "value-chain",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "316b91b0-94e8-4baa-80f6-f93acc7566e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.06,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1. Jarocha J, et al. Blood 2018;132(Supplement 1):2559. 2. Mascarenhas J, et al. Haematologica 2017;102(2):327-335. 3. Singer J, et al. Abstract #1874. Oral presentation ASH 2014. 4. Fisher D, et al. Leukemia 2019;33(8):1978-1995. 5. Lai HY, et al. Blood Adv 2019;3(2):122-131. 6. Balka KR, et al. J Leukoc Biol. 2019;105(2):339-351.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "047d0f0e-1e30-4a66-b326-e8b0bd017655",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.06,
        "y": 0.17
      },
      "kind": "title",
      "text": "VONJO is a JAK2 and IRAK1 inhibitor, with sparing of JAK1",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6ae5681-ff17-42ad-a21a-1955cb8eff0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "The Unique Profile of VONJO",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc4ac700-0da9-47e6-9914-2e7cbee21131",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 6,
      "beatId": "622c378e-8164-465f-9065-8c48989b5856",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": null,
      "evidence": "VONJO is a JAK2 and IRAK1 inhibitor, with sparing of JAK1",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "aa05f65e-18ae-4823-9eab-24ea42a6bc92",
      "evidence": "The Needs of the Myelofibrosis Market and VONJO's benefits",
      "position": 0,
      "objective": "Highlight the cost of inaction in the myelofibrosis market",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}